In addition to its potential as a “stand-alone
Post# of 154782
(Total Views: 447)
Posted On: 07/01/2025 11:08:10 AM
In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting.
(12)
(0)